Journal of Neonatal Surgery
ISSN(Online): 2226-0439
Vol. 14, Issue 25s (2025)
https://www.jneonatalsurg.com

Smarter Dosing for the Tiniest Patients: AI in Neonatal Pharmacology

Dr. Manjula M J[*1], Dr. Bhavya S[2], Mrs. Swetha M J[3]

[*1]Assistant Professor, Department of Pharmacology, Rajarajeswari Medical College and Hospital, Dr. M.G.R Educational and Research Institute, India manjula.mj03@gmail.com

[2]SNCU Paediatrician, Sir. C.V. Raman General Hospital, Indiranagar, Bangalore, India

[3]Swetha M J, Senior Grade Lecturer, Computer Science & Engineering, Dept, DRR government Polytechnic, Davangere, Karnataka, India

Cite this paper as: Dr. Manjula M J, Dr. Bhavya S, Mrs. Swetha M J, (2025) Smarter Dosing for the Tiniest Patients: AI in Neonatal Pharmacology. *Journal of Neonatal Surgery*, 14 (25s), 586-590.

ABSTRACT

Artificial Intelligence (AI) is revolutionizing healthcare, particularly in precision medicine and clinical decision-making. In neonatal care, accurate dosing of the drugs, fluids, in case of surgeries, the required anesthetics and analgesics is critical for patient safety and outcomes. This review explores the current landscape of AI-based dosage algorithms used in intraoperative and postoperative neonatal care, evaluating their development, application, performance, and clinical integration. We discuss role of machine learning models, data sources, algorithmic transparency, and ethical considerations, challenges and future directions in neonatal care with special emphasize of surgical and intensive care.

1. INTRODUCTION

Intraoperative and postoperative periods are critical junctures in neonatal care, where medication dosing must be carefully optimized to balance efficacy and safety. Traditionally, neonatologists and pediatric anesthesiologists rely on experience and population-based guidelines. However, these methods can result in underdosing or overdosing due to individual variability in neonates [1]. Artificial Intelligence (AI), and particularly machine learning (ML), offers a data-driven approach to personalizing drug dosages in real time, potentially improving outcomes for this vulnerable population.

The Importance of Accurate Dosing in Neonatal Care

Neonates, especially those born preterm, present unique physiological characteristics that challenge standardized pharmacological care. Factors such as immature hepatic and renal function, fluctuating fluid compartments, and rapid developmental changes affect drug metabolism and distribution [2]. Inappropriate dosing can result in increased morbidity, prolonged hospitalization, or even mortality. AI-based tools promise to enhance dosing accuracy by integrating multifactorial data, including genetic, physiologic, and pharmacokinetic profiles. This personalized approach holds the potential to minimize adverse drug reactions, reduce dependency on empirical dosing strategies, and better predict patient-specific drug efficacy.

Moreover, specific conditions such as patent ductus arteriosus, neonatal sepsis, and respiratory distress syndrome may require rapid pharmacological intervention with drugs that have narrow therapeutic windows. An AI-assisted system could continuously monitor real-time physiological parameters and suggest optimized dosing regimens, adapting as patient conditions evolve.

Overview of AI and Machine Learning in Healthcare

AI encompasses a broad range of technologies that simulate human intelligence. In healthcare, machine learning—a subset of AI—employs algorithms to identify patterns within large datasets and make predictions or decisions without explicit programming [3]. Techniques such as supervised learning, unsupervised learning, reinforcement learning, and deep learning are commonly employed in the development of predictive models for dosage guidance.

In neonatal care, these techniques are used to model complex, nonlinear interactions between patient variables such as weight, gestational age, metabolic rate, and prior drug responses. For example, supervised learning can be used to predict optimal dosing for a given drug based on a neonate's historical response data. Deep learning approaches, including convolutional and recurrent neural networks, are increasingly being explored for their ability to process multimodal data, including images, vital signs, and genomics.

AI Algorithms in Intraoperative Neonatal Care

During surgery, neonates require precise administration of anesthetics, muscle relaxants, and fluid management. AI algorithms assist in real-time monitoring and decision-making by analyzing data from multiple sensors, including heart rate, oxygen saturation, and end-tidal CO2 [4]. Closed-loop systems, which use AI to automatically adjust drug delivery based on physiological feedback, have shown promising results in simulated environments and pilot clinical studies [5].

One such system involves the integration of pharmacokinetic-pharmacodynamic (PK-PD) models with AI to personalize anesthesia depth. These models continuously adjust drug infusion rates in response to feedback from monitoring systems, potentially reducing the risk of awareness under anesthesia and adverse effects from overdose. AI systems also support dynamic fluid management by predicting fluid responsiveness using real-time hemodynamic data, thereby reducing perioperative complications such as hypotension and organ hypoperfusion.

Postoperative Pain Management and AI

Pain assessment in neonates is complex due to their inability to verbalize discomfort. AI models using facial recognition, cry analysis, and physiological parameters have been developed to assess pain more objectively [6]. Once pain is detected, AI dosage algorithms can recommend analgesic dosages tailored to the neonate's physiological state, history, and response patterns [7]. These systems aim to minimize opioid exposure while ensuring effective pain relief.

Recent developments include AI-powered monitoring systems that combine video, audio, and biosensor inputs to continuously assess a neonate's pain level. Algorithms analyze changes in facial muscle movement, vocalization patterns, and physiological data to determine the necessity and extent of analgesia. These insights can trigger alerts for medical staff or automatically adjust medication via smart infusion pumps.

Additionally, AI can be used to predict the duration of postoperative pain and calculate the likely trajectory of pain resolution, aiding clinicians in planning appropriate tapering strategies and avoiding prolonged opioid use. This predictive capability is especially crucial in preterm neonates, where long-term neurodevelopmental outcomes can be affected by inadequate pain control or excessive sedation.

Data Sources and Model Training

The development of AI-based dosage systems depends on high-quality data, including electronic health records (EHRs), pharmacokinetic datasets, biosensor data, and genomics [8]. Training these models requires large and diverse datasets to ensure robustness and generalizability. Federated learning is emerging as a method to build powerful models without centralized data storage, thus maintaining data privacy [9].

EHRs offer longitudinal data on dosing patterns, medication effectiveness, adverse reactions, and clinical outcomes. Coupled with real-time sensor data, these datasets allow AI models to account for immediate physiological changes. Integrating genomic data enables prediction of drug metabolism based on genetic polymorphisms, particularly in enzymes like CYP450 variants that influence drug metabolism.

Model training also incorporates reinforcement learning techniques, where algorithms learn optimal dosing strategies through trial and error using simulated environments. Synthetic data augmentation and transfer learning are additional strategies used to overcome the limitations of small neonatal datasets, ensuring that the models perform well across diverse clinical scenarios.

Validation and Clinical Implementation

Before AI dosage systems can be deployed in clinical settings, they must undergo rigorous validation through retrospective analyses, simulations, and prospective trials [10]. Regulatory bodies such as the FDA and EMA are developing frameworks to evaluate AI in medicine. Clinical adoption also depends on integration with existing workflows, clinician trust, and interoperability with health IT systems [11].

Implementation success stories include AI platforms embedded in anesthesia workstations that provide real-time dosing suggestions and monitor hemodynamic stability. These platforms require user-friendly interfaces and clinician override capabilities to ensure safe application. Moreover, continuous performance monitoring and post-deployment validation are necessary to account for clinical drift and changing patient populations.

Institutional support, standardized protocols, and dedicated training programs are essential for the successful uptake of AI systems in neonatal units. Engaging clinicians in the co-design of AI tools improves acceptance and ensures that the technology complements rather than disrupts clinical practice.

Ethical Considerations

The use of AI in neonatal care raises several ethical questions, including informed consent, data privacy, algorithmic bias, and transparency [12]. Since neonates cannot consent, parental understanding and agreement are essential. Additionally, ensuring that AI algorithms do not perpetuate biases found in training data is critical to equity in healthcare delivery.

Transparency in algorithmic decision-making is vital for trust. Explainable AI (XAI) methods aim to clarify how decisions are made, allowing clinicians and parents to understand the rationale behind dosing suggestions. Maintaining data privacy is especially important in neonatal care due to the sensitivity of genetic and clinical data. [12,13]

Furthermore, ethical deployment involves equitable access to AI tools across various healthcare settings, including low-resource environments. This ensures that technological advancements do not widen existing disparities in neonatal health outcomes.

2. CHALLENGES AND LIMITATIONS

Limited Availability of High-Quality Data

Neonatal datasets are often small, heterogeneous, and incomplete due to the rarity of specific conditions, ethical concerns in data collection, and variability in clinical documentation.[14] Most machine learning algorithms require large volumes of high-quality labeled data for effective training, and generalizing across different neonatal populations is challenging.

Lack of Standardization

There is currently no standardized protocol for developing, validating, or benchmarking AI algorithms for neonatal dosing. Differences in data formats, outcome measures, and dosing guidelines across institutions impede the scalability and reproducibility of AI models. [15]

Algorithmic Transparency and Interpretability

Many AI models, particularly those based on deep learning, function as “black boxes” with limited interpretability. This lack of transparency hinders clinician trust and complicates the clinical validation process, [16] especially in critical scenarios such as dose calculation for high-risk neonates.

Lack of Generalizability

AI models trained in specific hospitals or regions may not perform well in different clinical environments due to variations in patient demographics, treatment protocols, or resource availability. Without external validation, such models can produce inaccurate or unsafe dosage recommendations. [17]

Technological and Infrastructural Constraints

Implementing AI tools demands robust IT infrastructure, interoperability between systems, and continuous technical support—all of which may be lacking in resource-limited settings. This disparity can widen the digital divide and limit access to advanced neonatal care technologies. [18]

Limited Real-Time Capabilities

Many AI systems operate retrospectively or require significant processing time, which restricts their utility in acute, time-sensitive neonatal settings like surgery or intensive care. There have been ongoing trials in regular neonatal care. Developing lightweight, real-time algorithms suitable for bedside deployment remains a technical hurdle. [19]

Underrepresentation of Neonatal Pharmacogenomics

AI models incorporating genetic data often rely on adult pharmacogenomic databases, leading to inaccurate assumptions in neonates. [20] The lack of comprehensive neonatal-specific pharmacogenomic data limits the precision of AI-based dose optimization.

Clinician Resistance and Disruption of the workflow

Resistance to adopting AI systems stems from fears of loss of clinical autonomy, potential for automation bias, and increased cognitive load from interacting with complex interfaces. [21] If not carefully integrated, AI tools can disrupt established clinical workflows.

Continuous Model Maintenance

AI algorithms require periodic updates and retraining to reflect evolving clinical guidelines, drug approvals, and population dynamics. Maintaining model accuracy and relevance over time necessitates ongoing monitoring, which can be resource-intensive. [22]

Future Directions

Advancements in wearable technology, integration of multi-omics data, and development of explainable and adaptive AI models are shaping the future of personalized neonatal dosing. Collaborative efforts between clinicians, data scientists, and regulatory agencies are crucial for translating these technologies from bench to bedside. Research into long-term outcomes and cost-effectiveness will further support their adoption [23,24].

Future systems may incorporate continuous glucose monitoring, EEG-based assessments of neurological status, and metabolic profiling to dynamically adapt drug dosages. Integration with robotic-assisted surgery and smart ICU environments will enable seamless, real-time AI-supported decision-making.

In parallel, open-access platforms and data-sharing initiatives are essential to create large-scale neonatal datasets for training and benchmarking AI algorithms. Global collaborations and public-private partnerships can help overcome funding and technical barriers, accelerating innovation and implementation.



Figure 1: Flow chart illustrating the probable workflow of AI in quantifying the dose adjustments for neonates

3. CONCLUSION

AI-based dosage algorithms hold significant promise for enhancing intraoperative and postoperative neonatal care. By leveraging vast datasets and advanced computational models, these systems can personalize treatment, reduce medication errors, and improve outcomes for neonates. Continued interdisciplinary collaboration and rigorous validation are essential for their successful clinical integration.

REFERENCES

[1] Anand KJS, Hickey PR. Pain and its effects in the human neonate and fetus. N Engl J Med. 1987;317(21):1321-9.

[2] Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE. Developmental pharmacology—drug disposition, action, and therapy in infants and children. N Engl J Med. 2003;349(12):1157-67.

[3] Jiang F, Jiang Y, Zhi H, Dong Y, Li H, Ma S, Wang Y, Dong Q, Shen H, Wang Y. Artificial intelligence in healthcare: past, present and future. Stroke Vasc Neurol. 2017;2(4):230-43.

[4] Carvalho B, Clark DJ, Yeomans DC, Angst MS. The neurophysiology of pain perception and implications for anesthetic management. J Clin Anesth. 2008;20(1):1-14.

[5] Liu NT, Salinas J. Machine learning for predicting outcomes in trauma. Shock. 2017;48(5):504-10.

[6] Zamzmi G, Pai C-Y, Goldgof D, Kasturi R, Sun Y, Ashmeade T. Automated pain assessment in neonates: a survey. IEEE Trans Affect Comput. 2017;9(3):349-65.

[7] van Dijk M, Roofthooft DW, Anand KJ, Guldemond F, Simons S, Tibboel D. Taking up the challenge of measuring prolonged pain in (premature) neonates: the COMFORT neo scale seems promising. Clin J Pain. 2009;25(7):607-16.

[8] Lee J, Scott DJ, Villarroel M, Clifford GD, McCormick KE, Silva I, et al. Open-source EHR for AI research: the MIMIC database. Comput Cardiol. 2011;38:139-42.

[9] Rieke N, Hancox J, Li W, Milletari F, Roth HR, Albarqouni S, et al. The future of digital health with federated

learning. NPJ Digit Med. 2020;3:119.

[10] Topol EJ. High-performance medicine: the convergence of human and artificial intelligence. Nat Med. 2019;25(1):44-56.

[11] Kelly CJ, Karthikesalingam A, Suleyman M, Corrado G, King D. Key challenges for delivering clinical impact with artificial intelligence. BMC Med. 2019;17(1):195.

[12] Vayena E, Blasimme A, Cohen IG. Machine learning in medicine: addressing ethical challenges. PLoS Med. 2018;15(11):e1002689.

[13] Sendak MP, D'Arcy J, Kashyap S, Gao M, Nichols M, Corey K, Ratliff W, Balu S. A path for translation of machine learning products into healthcare delivery. EMJ Innov. 2020;4(1):70-6.

[14] Johnson AEW, Ghassemi MM, Nemati S, Niehaus KE, Clifton DA, Clifford GD. Machine learning and decision support in critical care. Proc IEEE. 2016;104(2):444-66.

[15] Saria S, Butte A, Sheikh A. Better medicine through machine learning: What's real, and what's artificial? PLoS Med. 2018;15(12):e1002721.

[16] Rudin C. Stop explaining black box machine learning models for high stakes decisions and use interpretable models instead. Nat Mach Intell. 2019;1(5):206-15.

[17] Badgeley MA, Zech JR, Oakden-Rayner L, Glicksberg BS, Liu M, Gale W, et al. Deep learning predicts hip fracture using confounding patient and healthcare variables. NPJ Digit Med. 2019;2:31.

[18] Char DS, Shah NH, Magnus D. Implementing machine learning in health care—addressing ethical challenges. N Engl J Med. 2018;378(11):981-3.

[19] Panch T, Szolovits P, Atun R. Artificial intelligence, machine learning and health systems. J Glob Health. 2018;8(2):020303.

[20] Vincent JL, Singer M. Critical care: advances and future perspectives. Lancet. 2010;376(9749):1354-61.

[21] Blake K, Prasad B, Burckart GJ. Pediatric pharmacogenomic data: Implications for AI in dosing. Clin Pharmacol Ther. 2021;110(3):582-4.

[22] Shortliffe EH, Sepúlveda MJ. Clinical decision support in the era of artificial intelligence. JAMA. 2018;320(21):2199-200.

[23] Cabitza F, Rasoini R, Gensini GF. Unintended consequences of machine learning in medicine. JAMA. 2017;318(6):517-8.

[24] Esteva A, Robicquet A, Ramsundar B, Kuleshov V, DePristo M, Chou K, Cui C, Corrado G, Thrun S, Dean J. A guide to deep learning in healthcare. Nat Med. 2019;25(1):24-9.